NCT00454545已完成2 期
Atorvastatin in Moderate Active Crohns Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Inflammatory markers in plasma before and after treatment.
研究概览
简要总结
Open pilot study to collect information regarding the effect of atorvastatin on patients with active Crohns disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of Crohns disease
- •C-reactive protein level > 2 mg/L in absence of an infection
- •Fecal calprotectin > 250 mg/kg or CDAI > 150
排除标准
- •CDAI > 450
- •Prednisolone dosage above 15 mg/day
结局指标
主要结局
Inflammatory markers in plasma before and after treatment.
次要结局
- Change in clinical activity index and mucosal inflammation after treatment.
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
Atorvastatin in moderat active Crohns diseaseCrohn's disease is an idiopathic chronic inflammatory bowel disease thought to result from inappropriate and ongoing activation of the mucosal immune system driven by the presence of normal luminal flora. It may affect the hole gastrointestinal tract, from mouth to rectum, with symptoms such as diarrhea, weight lose, malabsorption, abdominal pain and fever.EUCTR2005-000496-17-SERegion Skåne12
Unknown
不适用
Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot StudyCrohn's DiseaseNCT00599625University of Virginia40
撤回
不适用
Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)Complication of Renal DialysisNCT02764736Albert Einstein Healthcare Network
Unknown
2 期
An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT00432354Buddhist Tzu Chi General Hospital40
已完成
2 期
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF TherapyCrohn's DiseaseNCT00771667Centocor, Inc.526